List of Excipients in API trametinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing trametinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | MEKINIST | trametinib | 0078-0666 | CELLULOSE, MICROCRYSTALLINE | |
| Novartis Pharmaceuticals Corporation | MEKINIST | trametinib | 0078-0666 | CROSCARMELLOSE SODIUM | |
| Novartis Pharmaceuticals Corporation | MEKINIST | trametinib | 0078-0666 | FERRIC OXIDE RED | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for trametinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
trametinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
trametinib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
trametinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
trametinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSES
trametinib drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
trametinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
trametinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
trametinib drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
trametinib drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
trametinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
trametinib drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
trametinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-1105 |
| >Company | >Ingredient | >NDC |
trametinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | trametinib | 0078-0666 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch